ONCONEXT TISSUE

ONCONEXT TissueTM genetic tests were planned for oncological use in order to detect somatic mutations, related to solid tumors, on tissue biopsy samples.

ONCONEXT TissueTM genetic tests TM employ the innovative Next Generation Sequencing (NGS) technology, which make it possible to detect, in an extremely sensitive way, the presence of somatic mutations even from a small amount of tumor tissue.

Simultaneous detection of different mutations allows to better understand the genomic profile of the tumor and to adopt the most suitable treatment.

ONCONEXT TissueTM genetic testsTM were planned for oncological use, for oncology patients, with different clinical and diagnostic purposes:

  • Tumor profiling for the correct application of precision medicine. OncoNext Tissue™ Monitor can provide to oncologist  useful information to shape a personal treatment plan
  • Providing Prognostic information
  • Patient support for the admission to a Clinical Trial: it’s an additional function of OncoNext Tissue™test, aimed to the identification of specific clinical trial in which the patient falls into eligibility criteria.

ONCONEXT TISSUETM TESTSTM ARE PERFORMED FROM A TISSUE SAMPLE: FRESH OR PARAFFIN EMBEDDED

ONCONEXT TISSUE test TM was planned to detect, from a tissue sample, somatic mutations on the main genes involved in tumor development processes.

ONCONEXT Tissue testsTM include the study of specific panels custom-designed to meet the different diagnostic needs:

DOWNLOAD ONCONEXT TISSUE TM
BROCHURE 

tissue-brochure-onconext

ASK FOR MORE INFORMATION ABOUT THE TEST

    Name (required)

    Email (required)

    Choose the type of test you require

    Message

    I have read and acceptPrivacy Policy